Contribution: Industrial Research Assistance Program – Contributions to Firms
Paradox Immunotherapeutics Incorporated
$73,524.00
MNC Collab - PACAAL - In vivo potency assessment of candidate antibodies (LX-96) for AL amyloidosis
FY 2024-25 · 2024-12-04
Summary
As part of Multinational Corporate Collaboration Program, the project “PACAAL” will focus on using established mouse models to evaluate 4 top candidate antibodies co-developed by Paradox and Eli Lilly for the treatment of kappa light chain amyloidosis. After in vivo evaluation of the candidates, we will nominate a development candidate to move forward in IND-enabling studies.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
758832877
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2025-07-31
Agreement Number
1027009
Agreement Start Date
2024-12-04
Agreement Title
MNC Collab - PACAAL - In vivo potency assessment of candidate antibodies (LX-96) for AL amyloidosis
Agreement Title (French)
PCM - PACAAL - Évaluation in vivo de l’activité des anticorps candidats (LX-96) pour l’amylose AL
Agreement Type
Contribution
Agreement Value
$73,524.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
As part of Multinational Corporate Collaboration Program, the project “PACAAL” will focus on using established mouse models to evaluate 4 top candidate antibodies co-developed by Paradox and Eli Lilly for the treatment of kappa light chain amyloidosis. After in vivo evaluation of the candidates, we will nominate a development candidate to move forward in IND-enabling studies.
Description (French)
Dans le cadre du programme de collaboration des entreprises multinationales, le projet « PACAAL » se concentrera sur l’utilisation de modèles murins établis pour évaluer quatre anticorps candidats de premier plan codéveloppés par Paradox et Eli Lilly pour le traitement de l’amylose à chaîne légère kappa. Après l’évaluation in vivo des candidats, nous nommerons un candidat au développement pour passer aux études de validation de la demande d’autorisation d’essai clinique (IND).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
758832877
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Paradox Immunotherapeutics Incorporated
Recipient Postal Code
M5G 0B7
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2024-2025-Q4-1027009
